Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Breaking News
Two men, woman shot at Fayetteville Road intersection in Durham
Breaking News
2-year-old among 3 people shot in Durham shooting on East Cornwallis Road
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aslan Pharmaceuticals Ltd ADR
(NQ:
ASLN
)
0.3200
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Jun 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1
Open
0.3200
Bid (Size)
0.3260 (3)
Ask (Size)
0.3650 (38)
Prev. Close
0.3200
Today's Range
0.3200 - 0.3200
52wk Range
0.3100 - 4.190
Shares Outstanding
402,116,835
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
June 20, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
June 20, 2024
Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements this morning!
Via
InvestorPlace
Performance
YTD
-41.82%
-41.82%
1 Month
-33.33%
-33.33%
3 Month
-53.96%
-53.96%
6 Month
-29.98%
-29.98%
1 Year
-91.86%
-91.86%
More News
Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
June 17, 2024
Via
Benzinga
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
June 14, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
May 21, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLN Stock Earnings: ASLAN Pharma Beats EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
May 07, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
May 02, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
April 30, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
April 26, 2024
Via
Benzinga
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
April 24, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
April 22, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
April 19, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLN Stock Earnings: ASLAN Pharma Misses EPS for Q4 2023
April 12, 2024
Via
InvestorPlace
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
April 12, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
March 27, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO
March 16, 2024
Via
Talk Markets
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
March 12, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
March 11, 2024
Via
Benzinga
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
March 11, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 06, 2024
Via
Benzinga
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
March 06, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
February 29, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.